We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can AI Keep ISRG Ahead of Rising Robotic Surgery Competition?
Read MoreHide Full Article
Key Takeaways
Intuitive Surgical is expanding da Vinci 5 with AI-driven insights, simulation and telepresence capabilities.
More than 100 planned software updates aim to improve usability, efficiency and care-team workflows.
Force Feedback, AI and a nearly 13,000-system base deepen Intuitive Surgical's competitive moat.
Intuitive Surgical’s (ISRG - Free Report) technology strategy is becoming increasingly important as competition in robotic surgery intensifies. The company is using artificial intelligence, software and data-driven capabilities to make its da Vinci ecosystem more useful beyond the core robotic platform.
In the second quarter, Intuitive Surgical highlighted the increasing adoption of My Intuitive Surgical+, an integrated da Vinci 5 offering that combines telepresence, simulation and AI-driven case insights. Although the initial renewal cohort was small, no customers opted out, suggesting early acceptance of the platform’s broader digital capabilities.
The company is also leveraging da Vinci 5’s computing capabilities to create a continuing stream of software enhancements. Intuitive Surgical has planned more than 100 updates, with the first phase focused on telepresence, simulation-based training and care-team workflow.
Several updates are designed to improve usability and efficiency, including tools that reduce communication between surgeons and care teams, enable multiple robotic arms to be adjusted before or during procedures, and provide a digital ruler for intraoperative measurements. Management believes these recurring upgrades can progressively increase the attractiveness of da Vinci 5 and support a multi-year upgrade cycle.
Force Feedback provides another layer of differentiation. Intuitive Surgical reported that a prospective study associated its use with faster return of bowel function following partial and radical nephrectomy. The study data showed that 63% of patients recovered within one day versus 28% without Force Feedback. Force Feedback instruments are excluded from the company’s extended-use program, underscoring their role as an innovation-driven component of the ecosystem.
AI-driven insights, continuous software development, simulation, workflow optimization and advanced instrumentation strengthen Intuitive Surgical’s competitive moat. Its nearly 13,000-system installed base and broad Gen 4 ecosystem provide a platform on which these innovations can compound, potentially keeping the company ahead of insurgent companies focused solely on robotic hardware.
Peer Update
Globus Medical (GMED - Free Report) is moving beyond robotic navigation toward a broader data, analytics and AI-driven surgical intelligence ecosystem. The company is using data from patient treatment to learn and improve patient selection and surgical execution, with the goal of assisting surgeons rather than replacing clinical judgment. This strategy is being integrated with the Excelsius platform, where digital preoperative planning can be uploaded to ExcelsiusGPS and ExcelsiusHub for robotically navigated screw placement.
With more than 60 product-development projects underway, Globus Medical views AI as a long-term differentiator capable of connecting intelligent patient selection, proceduralization and complementary implants to improve surgical outcomes.
Stereotaxis (STXS - Free Report) is taking a more direct approach to embedding AI into its robotic ecosystem through Synchrony and SynX, its digital surgery platforms. Management describes these systems as providing enhanced workflow, remote connectivity and smart AI capabilities, with Synchrony serving as a cockpit for robotic procedures as well as an independent opportunity in non-robotic operating rooms.
STXS plans to incorporate intelligent decision-support features into Synchrony and add automation to its robotic platforms. The company sees AI as part of a much longer digital-surgery roadmap, alongside telerobotics and broader automation. Stereotaxis believes these capabilities can ultimately expand the clinical and commercial value of its robotic platform beyond today’s applications.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 33.6% so far this year compared with a 10.8% decline of the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 31.8X, above the industry average. But, it is significantly lower than its five-year median of 67.91X. ISRG carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2026 earnings implies a 20.3% rise from the year-ago period’s level.
View the Zacks #1 Rank List
Image: Shutterstock
Can AI Keep ISRG Ahead of Rising Robotic Surgery Competition?
Key Takeaways
Intuitive Surgical’s (ISRG - Free Report) technology strategy is becoming increasingly important as competition in robotic surgery intensifies. The company is using artificial intelligence, software and data-driven capabilities to make its da Vinci ecosystem more useful beyond the core robotic platform.
In the second quarter, Intuitive Surgical highlighted the increasing adoption of My Intuitive Surgical+, an integrated da Vinci 5 offering that combines telepresence, simulation and AI-driven case insights. Although the initial renewal cohort was small, no customers opted out, suggesting early acceptance of the platform’s broader digital capabilities.
The company is also leveraging da Vinci 5’s computing capabilities to create a continuing stream of software enhancements. Intuitive Surgical has planned more than 100 updates, with the first phase focused on telepresence, simulation-based training and care-team workflow.
Several updates are designed to improve usability and efficiency, including tools that reduce communication between surgeons and care teams, enable multiple robotic arms to be adjusted before or during procedures, and provide a digital ruler for intraoperative measurements. Management believes these recurring upgrades can progressively increase the attractiveness of da Vinci 5 and support a multi-year upgrade cycle.
Force Feedback provides another layer of differentiation. Intuitive Surgical reported that a prospective study associated its use with faster return of bowel function following partial and radical nephrectomy. The study data showed that 63% of patients recovered within one day versus 28% without Force Feedback. Force Feedback instruments are excluded from the company’s extended-use program, underscoring their role as an innovation-driven component of the ecosystem.
AI-driven insights, continuous software development, simulation, workflow optimization and advanced instrumentation strengthen Intuitive Surgical’s competitive moat. Its nearly 13,000-system installed base and broad Gen 4 ecosystem provide a platform on which these innovations can compound, potentially keeping the company ahead of insurgent companies focused solely on robotic hardware.
Peer Update
Globus Medical (GMED - Free Report) is moving beyond robotic navigation toward a broader data, analytics and AI-driven surgical intelligence ecosystem. The company is using data from patient treatment to learn and improve patient selection and surgical execution, with the goal of assisting surgeons rather than replacing clinical judgment. This strategy is being integrated with the Excelsius platform, where digital preoperative planning can be uploaded to ExcelsiusGPS and ExcelsiusHub for robotically navigated screw placement.
With more than 60 product-development projects underway, Globus Medical views AI as a long-term differentiator capable of connecting intelligent patient selection, proceduralization and complementary implants to improve surgical outcomes.
Stereotaxis (STXS - Free Report) is taking a more direct approach to embedding AI into its robotic ecosystem through Synchrony and SynX, its digital surgery platforms. Management describes these systems as providing enhanced workflow, remote connectivity and smart AI capabilities, with Synchrony serving as a cockpit for robotic procedures as well as an independent opportunity in non-robotic operating rooms.
STXS plans to incorporate intelligent decision-support features into Synchrony and add automation to its robotic platforms. The company sees AI as part of a much longer digital-surgery roadmap, alongside telerobotics and broader automation. Stereotaxis believes these capabilities can ultimately expand the clinical and commercial value of its robotic platform beyond today’s applications.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 33.6% so far this year compared with a 10.8% decline of the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 31.8X, above the industry average. But, it is significantly lower than its five-year median of 67.91X. ISRG carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2026 earnings implies a 20.3% rise from the year-ago period’s level.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.